Summary
In order to explore the value of p63, smooth muscle actin (α-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining. By using immunohistochemistry, the expression of p63, α-SMA and CK5/6 was detected. The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and α-SMA. In 19 cases of ductal carcinoma in situ (DCIS) and 7 cases of intraductal papillary carcinoma, α-SMA positive cells formed a layer of continuous embroider-shaped structure and the p63 positive cells formed a layer of evenly separated embroider-shaped structure around the ducts. There was no cross-reaction between p63 and interstitial myofibroblasts and vascular smooth muscle cells. In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100 %. In 5 cases of atypical ductal hyperplasia, there were few positive cells in the ducts. In 19 cases of CDIS, no tumor cells expressed CK5/6. In 19 cases of invasive ductal carcinoma, almost no CK5/6 was detectable. It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells. CK5/6 is of value in differentiating ductal proliferation of varying degrees, especially in the differentiation between cancerous and non-cancerous changes. Simultaneous detection of p63, CK5/6 and α-SMA can help increase the diagnostic accuracy of breast diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barbareschi M, Pecciarini L, Cangi M G et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol, 2001,25(8):1054–1060
Werling R W, Hwang H, Yaziji H et al. Immunohistochemical distinction of invasive from noninvasive breast lesions. Am J Surg Pathol, 2003,27(1):82–90
Batistatou A, Stefanou D, Arkoumani E et al. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo, 2003,17(6):573–576
Reis-Filho J S, Schmidtt F C. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol, 2002,9(5):280–289
Jing H B, Ding Y Q, Gao L X. Role of p63 protein in differential diagnosis of breast benign and malignant lesions. J Diag Pathol (Chinese), 2004,11(5):21–23, 88
Liu T Q, Wang M H, Xing G Y et al. Expression and significance of p63 protein in breast lesions. J Diag Pathol (Chinese), 2004,11(4):34–36,39
Moritani S, Kushima R, Sugihara H et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol, 2002,15(4):397–405
Douglas-Jones A, Shah V, Morgan J et al. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology, 2005,47(2):202–208
Lacroix-Triki M, Mery E, Voigt J J et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch, 2003,442(6):548–554
Author information
Authors and Affiliations
Additional information
DING Yanping, female, born in 1965, Associate Professor
Rights and permissions
About this article
Cite this article
Ding, Y., Ruan, Q. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J. Huazhong Univ. Sc. Technol. 26, 405–407 (2006). https://doi.org/10.1007/s11596-006-0406-x
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11596-006-0406-x